Pharmaceutical

Bristol-Myers Squibb (NYSE:BMY) experienced a stronger than anticipated second quarter, with strong sales for new heart, hepatitis C, and cancer medicines increasing revenues.

Bristol-Myers Squibb (NYSE:BMY) experienced a stronger than anticipated second quarter, with strong sales for new heart, hepatitis C, and cancer medicines increasing revenues.
According to an article on Pharmaceutical Processing:

Bristol-Myers’ recent purchase of startup Flexus Biosciences Inc. resulted in an $869 million charge, plus most of the tax bill and quarterly loss. But it gives Bristol-Myers a company trying to develop immuno-oncology drugs with a different mechanism than Opdivo and Yervoy.
Excluding the acquisition charge and other one-time items, Bristol-Myers posted adjusted income of $890 million, or 53 cents per share. Analysts surveyed by FactSet were expecting 36 cents, on average.
The $130 million net loss amounted to 8 cents per share. In 2014’s second-quarter, Bristol-Myers posted net income of $333 million, or 20 cents per share.

 
Click here to read the full article on Pharmaceutical Processing.

MARKETS

Markets
TSX19062.91+345.79
TSXV647.33+15.54
DOW31500.68+823.32
S&P 5003911.74+116.01
NASD11607.62+375.43
ASX6528.40+19.90

COMMODITIES

Commodities
Gold1827.54+0.47
Silver21.15+0.03
Copper3.740.00
Palladium1879.51+6.50
Platinum911.26+4.32
Oil107.06+2.79
Heating Oil4.24+0.02
Natural Gas6.17-0.07

DOWNLOAD FREE REPORTS

×